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p53 is a powerful anti-tumoral molecule frequently inactivated by mutations or deletions in cancer.
However, half of all human tumors expresses wild-type p53, and its activation, by antagonizing its neg-
ative regulator Mdm2, might offer a new strategy for therapeutic protocol. In this work, we present a
molecular dynamics study on Mdm2 structure bound to two different known inhibitors with the aim
to investigate the structural transitions between apo-Mdm2 and Mdm2-inhibitor complexes. We tried
to gain information about conformational changes binding a benzodiazepine derivative inhibitor with
respect the known nutlin and the apo form. The conformational changes alter the size of the cleft and
were mainly in the linker regions, suggesting that the overall dynamic nature of Mdm2 is related to
dynamic movements in these regions.
 2012 Elsevier Inc. All rights reserved.1. Introduction
In response to DNA damage and other types of stress stimuli,
p53 causes cell-cycle arrest [1] or activates apoptosis [2,3]. In nor-
mal cells, p53 is held in check until needed by Mdm2 [4]. Harmful
mutations of p53 are common mechanisms for the loss of p53
wild-type activity in tumor cells [5]. But another important mech-
anism is overexpression of Mdm2, which leads to constitutive inhi-
bition of p53; this is commonly seen in cancerous cells containing
wild-type p53 [6,7]. Because of its importance in cancer develop-
ment, the p53–Mdm2 complex is a really interesting target for
anticancer drug design. It has been shown that a p53 homologue
is sufﬁcient to induce p53-dependent cell death in cells over-
expressing Mdm2 [8], and that a peptide as short as six residues
could bind to Mdm2 in the same manner [9]. Medicinal chemistry
modiﬁcations to the same 6-residue peptide dramatically in-
creased its inhibitory activity [10]. Small p53 mimics would be ex-
pected to disrupt the p53–Mdm2 complex. This anti-Mdm2
approach has been shown to re-establish p53 activities in malig-
nant tissues with ampliﬁed Mdm2 genes [11]. An increasing num-
ber of small-molecule p53–Mdm2 binding inhibitor has been
discovered in recent years, such as nutlins, but only few com-
pounds have acceptable cellular potency and selectivity for their
molecular target and might represent viable leads for development
of therapeutic agents [11].ll rights reserved.
tlin2; BDZ, benzodiazepine;
. Almerico).In order to design an effective p53 mimic as inhibitor of human
Mdm2, it is important to understand the p53–Mdm2 interaction at
the atomic level. Recently, in different molecular dynamics (MD)
studies, the p53–Mdm2 system was investigated to explore the
binding interface, and the effect of mutating key residues in the
human p53–Mdm2 complex [12–16]. For example, Carlson and
Zhong [13] have applied a 2 ns MD simulation to examine the
binding interface in the human p53–Mdm2 complex in order to
design a potent p53 mimic, which suggested that an additional
hydrofobic pocket should possibly be used to design new
Mdm2-inhibitors. More recently Verma et al. [17] used MD simu-
lations to investigate the binding of p53 and nutlin to Mdm2 and
MdmX. Simulations reveal that p53 has a higher afﬁnity for
Mdm2 than MdmX, driven by stronger electrostatic interactions.
The differences are more pronounced for nutlin because this is a
small molecule whose binding is driven by short range van der
Waals interactions and lacks the long range electrostatics that
mediate interactions with p53. In a work carried out on the X-
ray structure of MdmX bound to a single-domain antibody, Fersht
et al. [18] studied structural changes on removal of the ligands: the
binding pocket converged to a common conformation, indicating
that the differences are due to induced ﬁt. However, the residues
that comprise the Mdm2 lid are not conserved in MdmX; and also
crystal structure of nutlin2 complexed to Mdm2 (PDB ID: 1RV1)
used for the simulation does not contain information concerning
the lid. All these studies demonstrated as Mdm2 interconverts be-
tween different states in relation to the presence of p53 [19].
In this work we tried to gain information by means MD simula-
tions of Mdm2, complexed with a benzodiazepine derivative and
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tural transitions between apo-Mdm2 and Mdm2-inhibitor bound
forms. Moreover the behavior in presence of p53 and small-mole-
cules inhibitors was evaluated. Local and global dynamics are dis-
cussed and their implication for drug design addressed.2. Materials and methods
The GROMACS package [20,21] was used to perform molecular
dynamics simulations, using the force-ﬁeld parameter set 43A1.
The ligand was removed from the protein and 35 ns MD simula-
tions of the free receptor were ﬁrst performed, then 35 ns MD sim-
ulations of the Mdm2 complexed with the inhibitors were carried
out. The systems were embedded in a water box, the simple point
charge (SPC) water model, with margin of 9 Å between the protein
and the boundaries of the periodic box. Chlorine counterions were
added to produce a neutral charge on the system, and the simula-
tions were performed in constant NPT ensemble. Lennard-Jones
potentials were used to model the guest–host and guest–guest
interactions, force calculations were truncated at a distance of
1.4 nm. For the calculation of long-range electrostatic forces, the
particle-mesh Ewald (PME) method was used, with coulomb cut-
off set to 0.9 nm. The temperature was ﬁxed at 300 K using the
Berendsen thermostat and the Berendsen pressure coupling algo-
rithm was used to keep the pressure constant at 300 bar. A steep-
est-descent energy minimization of the systems was ﬁrst
performed to relax the solute-solvent contacts and in order to re-
move bad van der Waals contacts. The second step consisted in po-
sition-restrained MD, restraining the atom positions of the
macromolecule while letting the solvent move in the simulation,
to soak the water molecule into the protein. Finally, the third step
consisted of the MD simulation. The trajectory ﬁles were analyzed
by using GROMACS utilities. Moreover VEGA [22] and VMD [23]
programs were employed for trajectory analysis and to manipulate
the simulation snapshot structures.
The Induced Fit Protocol (IFD), developed by Schrödinger [24], is
a method for modeling the conformational changes induced by li-
gand binding. This protocol models induced ﬁt docking of one or
more ligands using the following steps:
1. Constrained minimization of the receptor with an RMSD cutoff
of 0.18 Å.
2. Initial glide docking of each ligand using a softened potential
(van der Waals radii scaling).
3. One round of prime side-chain prediction for each protein/
ligand complex, on residues within a given distance of any
ligand pose (5 Å).
4. Prime minimization of the same set of residues and the ligand
for each protein/ligand complex pose. The receptor structure
in each pose now reﬂects an induced ﬁt to the ligand structure
and conformation.
5. Glide redocking of each protein/ligand complex structure
within a speciﬁed energy of the lowest-energy structure. The
ligand is now rigorously docked, using XP Glide, into the
induced-ﬁt receptor structure.
6. Estimation of the binding energy (IFDScore) for each output
pose.
Each complex was then ranked according to the IFD score.3. Results and discussion
The conformational evolution of apo-Mdm2 and bound Mdm2
was investigated by 35 ns simulations. Crystal structure of the
Mdm2 complexed with the benzodiazepine derivative BDZ (PDBID: 1T4E) was used as starting model for simulations. The protein
comprises a minimal N-terminal p53 binding domain (residues
16–25), referred to as the lid. While structures of Mdm2 bound
to various inhibitors have been solved by X-ray crystallography
and NMR [25], no information is available concerning the lid
behavior in apo-Mdm2. The limited amount of experimental data
thereby precluded the accurate modeling of the lid and its precise
arrangement with respect to the cleft. In addition, it has been pro-
posed that the binding event induces global conformational
changes of Mdm2 [26].
Here, we report the characterization of the behavior of Mdm2,
including the lid, in the apo state (removing ligands), and in com-
plex with the inhibitors. Further by using the obtained apo state at
0 ns, a different inhibitor, IMZ (nutlin2), was docked and multiple
poses of the ligand complex were generated with Induced Fit
Docking [24]. This model reproduced a conformation nearly iden-
tical to the native pose of IMZ as found in 1RV1, in which the lid
was not solved, and that can be used in 35 ns MD simulation.
The structural changes resulting from the simulation can be,
ﬁrst, evaluated in terms of RMSD of the Ca-atoms of the bound
(Mdm2 + BDZ, Mdm2 + IMZ) and unbound (apo) systems (Fig. 1A).
The trajectory of unbound system maintains quite stable up to
about 10 ns and then increases by about 2 Å. After 20 ns increases
again, then it remains stable throughout the following 15 ns of the
simulation, with ﬂuctuation of about 0.5 Å. When the RMSD of the
apo form is compared to that of the Mdm2 bound to IMZ, it was ob-
served that during the ﬁrst 3.3 ns RMSD was similar and compara-
ble. Thereafter it showed a signiﬁcant increase, indicating major
structural deviations up to 11.3 ns. During the rest of the simula-
tion the dynamics of Mdm2 bound to IMZ remains very stable
and was very similar to apo-Mdm2. The RMSD of the Mdm2 bound
to BDZ appears different from the previous ones, and showed a sig-
niﬁcant increase during the ﬁrst 6 ns of simulation. After that point
the dynamics of the protein remained relatively stable, with ﬂuctu-
ation of about 0.5–0.6 Å. In this range, RMSD was comparable with
that observed in the Mdm2 bound to IMZ. However, during the rest
of the simulation, it showed a remarkable increase of the calcu-
lated value, therefore major conformational changes on the protein
take place.
Similar behavior of apo-Mdm2 was found in other studies
[13,27]. The trajectory of the p53–Mdm2 complex [13] was very
similar to that observed for Mdm2 bound to IMZ. p53–Mdm2 com-
plexes were highly ﬂexible in simulation, and the complexes exam-
ined by us appear to follow this trend.
The RMSD of backbone atoms in the binding pocket (Leu54,
Leu57, Ile61, Met62, Tyr67, Val75, Phe86, Phe91, Val93, Ile99,
and Ile103) is presented in Fig. 1B. In apo-Mdm2, the binding pock-
et was stable throughout the trajectory with ﬂuctuation below 0.5.
Binding pocket dynamics of Mdm2 bound to IMZ was very similar
to apo-Mdm2. Instead in presence of BDZ, the RMSD gradually
increased.
When the RMSD of the lid is compared for apo and bound
Mdm2 (Fig. 1C), it was observed that IMZ induced changes in the
lid conformation. The trajectory of lid in the apo Mdm2 is quite
stable over the timescale of simulation, whereas the RMSD of
Mdm2–IMZ lid was 2 Å during the ﬁrst 5 ns, but an increase of
about 2 Å was observed in subsequent ns. A rise in RMSD was ob-
served for Mdm2–BDZ lid between 1 and 24 ns. During the rest of
the simulation RMSD showed a signiﬁcant decrease, suggesting the
probable interaction between BDZ and the lid that helps to stabi-
lize lid conformation.
These results indicates the structural stability of apo protein,
while the RMSDs of bound systems suggested structural mobility.
The presence of inhibitors in the binding pocket caused a different
shift of the lid, originally located above the binding cleft. While IMZ
seems to push the lid away from the cleft, BDZ allows, in the last
Fig. 1. (A) RMSD of total structure, (B) RMSD of binding pocket, (C) RMSD of lid for Mdm2 apo (green) and bound forms [BDZ (blue); IMZ (red)]. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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movement of binding cleft is adaptive and the inhibitors induce
ﬂexibility at this point.We used PCA as a guide to identify signiﬁcant dynamic pro-
cesses from this very large data set. The ﬁrst step in PCA is the con-
struction of the covariance matrix, which captures the degree of
Fig. 2. (A) PCA computed for Mdm2 in various states. (B) Contributions of ﬁrst ten principal component. (C) RMSF of Mdm2: apo (green) and bound forms [BDZ (blue); IMZ
(red)]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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ance matrix is subsequently diagonalized, yielding a matrix of
eigenvectors and a diagonal matrix of eigenvalues. Each of theeigenvectors describes a collective motion of particles, where the
values of the vector indicate how much the corresponding atom
participates in the motion. The sum of the eigenvalues is a measure
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(7.07 nm2 in the case of Mdm2–BDZ, 4.25 nm2 for Mdm2–IMZ)
the total sum of eigenvalues of apo system was relatively small
(3.53 nm2), indicating a more rigid structure. PCA technique
decomposes the intrinsic ﬂexibility of a protein into motions of dif-
ferent frequencies of vibrations. These are then ordered such that
the ﬁrst component (PC1) characterizes the motion with the larg-
est amplitude and lowest frequency.
Principal components were computed for Mdm2 in various
states: apo, complexes with IMZ and with BDZ (Fig. 2A). PC1 dom-
inates the motions of Mdm2 bound to BDZ (covering 56% of overall
motion). The motion is more distributed across PC1 and PC2 in
Mdm2 bound to IMZ (21.5% PC1, 12.2% PC2) and apo-Mdm2Fig. 3. (A) Superimpositions of Mdm2 clusters apo forms. Backbones of apo-Mdm2 at 0 n
superimpositions of Mdm2 clusters bound to IMZ. Backbones of Mdm2–IMZ at 0 ns (blu
superimpositions of Mdm2clusters bound to BDZ. Backbones of apo-Mdm2 at 0 ns (blue
interpretation of the references to color in this ﬁgure legend, the reader is referred to th(11.7% PC1, 6% PC2). Histogram in Fig. 2B refers to the contribu-
tions of ﬁrst ten individual principal component to the overall ﬂuc-
tuations. The distribution of the structures in the phase space
deﬁned by PC1 and PC2 showed that bound states of the protein
with both inhibitors are more ﬂexible than apo one.
To quantitatively measure the mean backbone mobility for each
residue, the root mean square ﬂuctuations (RMSF) relative the
average structure of apo-Mdm2 were calculated (Fig. 2C). It was
observed that the mobility of the unbound system was relatively
low for the regions including residues 26–76. In this region the
RMSF was <1 Å. Few residues (42–44 and 69–71) displayed a
mobility higher than 1 Å, speciﬁcally, residues 69–71 which form
a hinge that connects helix a2 with the region formed by sheetss (blue), 10 ns (red), 20 ns (yellow) and 35 ns (green) are highlighted in the box; (B)
e), 10 ns (red), 20 ns (green) and 35 ns (turquoise) are highlighted in the boxes; (C)
), 10 ns (red), 20 ns (green) and 35 ns (turquoise) are highlighted in the boxes. (For
e web version of this article.)
Fig. 4. (A) Side-chain motions of Mdm2 apo forms at 10 ns (yellow), 20 ns (orange),
30 ns (purple). (B) Side-chain motions of Mdm2 bound to BDZ at 10 ns (yellow),
20 ns (green), 30 ns (red). (C) Side-chain motions of Mdm2 bound to IMZ at 10 ns
(yellow), 20 ns (orange), 30 ns (green). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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bility throughout the 35 ns simulation (RMSF > 1.3 Å) in the region
including amino acids 78–81. When comparing the mobility of
apo-Mdm2 to that observed for Mdm2 bound to IMZ, a very similar
trend of RMSF was observed. The mobility of Mdm2 bound to IMZ
is lower than apo-Mdm2, except for residues 61-74, in proximity of
the amino acids which constitute the hydrophobic binding cleft
(Met62, Tyr67, Val75). The residues that showed the highest ﬂexi-
bility were Lys70, Ser78, and Asn79 (RMSF about 1.5 Å), located
around the binding cleft. Residues which constitute binding cleft
showed higher degree of ﬂexibility. The higher RMSFs highlight
the ability to better adapt itself to ligand (BDZ, IMZ), and in partic-
ular benzodiazepine core seems to make the binding pocket much
more adaptive than imidazoline one.
To qualitatively analyze the conformational changes experi-
enced by the protein, the superimposition of three clusters of
structures was analyzed (Fig. 3).
Considering apo-Mdm2 superimpositions, we observed that the
lid was located just above the binding cleft in the ﬁrst 13 ns.
Between 13 and 19 ns, the lid displayed a movement outwards,
opening the binding site. In Mdm2–IMZ system, we observed that
the lid displayed a high degree of ﬂexibility and a large movement
away from the cleft. The helix a2 experienced an inward move-
ment toward the center of the cleft. Furthermore, sheets b10–b20
showed a movement toward the center of the binding cleft, leading
to a more closed conformation of the binding pocket. Similarly, in
the case of Mdm2–BDZ superimposition, the helix a20 experienced
an inward movement toward the center of mass of the cleft. The
hinge that connected helix a20 with sheets b20, the ﬂoor of the cleft,
showed a large movement toward the center of the binding cleft.
This inward movement was facilitated by the twisting motion of
the hinge formed by sheets b10 and b20. The shape of the binding
cleft changes and the cleft movement is inﬂuenced by the move-
ment of hinges and helices located around.
Another interesting feature observed in our simulations was the
dynamics of the side chains of key residues at the binding pocket,
Leu54, Leu57, Ile61, Met62, Tyr67, Val75, Phe86, Phe91, Val93,
Ile99, and Ile103. Leu57 is a residue that interacts with p53 via
the formation of a hydrogen bond between the Ne from Trp23
(p53) and the backbone carbonyl of Mdm2. When Mdm2 is un-
bound (Fig. 4A), Leu57 displayed rapid transitions going from
170 to +170. No signiﬁcant differences were observed in the
type of motions displayed by Met62, Tyr67, Val75, Phe86, and
Leu54. Also for Phe91 and Val93 no signiﬁcant differences in the
type of motions were observed for the ﬁrst 23 ns. After that point
they displayed rapid transitions.
In the case of Mdmd2 bound to BDZ (Fig. 4B) no signiﬁcant dif-
ferences were observed in the type of motions displayed by Leu54,
except rapid transitions going from 60to +164and from 145to
+178after 16 and 26 ns, respectively. A similar situation was no-
ticed for Leu57, which displayed transition movements in the
range from 160to +170, and for Met62. No signiﬁcant differences
were observed in the type of motions displayed by Tyr67 and
Phe86. Val75 displayed rapid transitions going from 170 to
+177and similar situation was noticed for Phe91 and Val93. Com-
paring the Mdm2–IMZ librational motions to those found in the
case of Mdm2–BDZ, a slight different behavior was observed
(Fig. 4C). Leu54, Leu57, Val75 and Val93 displayed transition
movements in the range from 180to +170, whereas no remark-
able differences were observed in the type of motions displayed
by Tyr67, Phe86 and Phe91. The binding of two different ligands
(IMZ and BDZ) to the cleft requires speciﬁc side-chain movements
and local arrangements of the cleft. Side-chain ﬂuctuations of the
amino acids located at the binding cleft allow the binding cleft to
be more ﬂexible and to adapt itself to incoming ligand.To investigate the binding mode of the two inhibitors, we ana-
lyzed the structure of the snapshot of Mdm2 bound to the two dif-
ferent compounds (IMZ and BDZ) obtained after 35 ns simulations.
When the Mdm2–IMZ at 0 ns was analyzed, IMZ interacts with
Gln72 through the hydroxyethyl group, which donates a hydrogen
bond to the side-chain oxygen of Gln72. We observed that one
bromophenyl group established non polar interaction with
Leu54, the other bromophenyl group with Leu57, Phe86, Phe91,
Ile99, and Ile103. In addition the hydroxyethyl side chain of IMZ
established non polar interaction with Tyr67 and Ile61. When the
protein-inhibitor complex, as obtained after 35 ns MD, was ana-
lyzed, we found that bromophenyl groups established non polar
interaction with Leu57, Gly58, Ile61, Val93 and His96. The
hydroxyethyl group of the IMZ formed non polar interaction with
Gln72, the piperazine group with Tyr67, and 2-ethoxy-4-methoxy-
phenyl group with His73 and Ala43.
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pockets of the peptide p53 side chains, and the Mdm2 interactions
with the inhibitor were largely nonspeciﬁc van der Waals contacts.
The BDZ pendant groups orient themselves to mimic the position of
the hydrophobic side chains on one face of the helical p53 peptide
ligand and thus act as an a-helix mimetic, with one chlorophenyl
moiety sitting in the Leu pocket, the other occupying the Trp pock-
et, and the 7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzodiazepine
moiety laying in the Phe pocket. When the protein-inhibitor com-
plex, as obtained after 35 ns MD, was analyzed, we found that chlo-
rophenyl groups established non polar interaction with Val93,
Lys94, His96, Tyr100 and Ile103, the core dioxobenzodiazepine ring
formed non polar interaction with Ile61, Tyr67, Lys94 and Gln72.
These ﬁndings are partially in agreement with the data reported
in Ref. [27], in which the authors performed a LDA with the aim
of identifying speciﬁc residues whose conformational changes are
the marker of the apo and p53-bound states of Mdm2 and MdmX.
In IMZ–Mdm2 two residues are identiﬁed as involved in the
shape arrangement of the p53 binding site: Gln72 and His73.
Gln72 and Tyr100 are identiﬁed in BDZ–Mdm2. Other residues
are involved in the shape arrangement of the binding site, namely
Ala43, Leu57, Gly58, Ile61, Tyr67, His73, Val93, Lys94, His96, and
Ile103.
Therefore ligands make extensive van der Waals contacts with
residues in the peptide binding cleft comprised of the structural
elements a2, b10, and a20. These residues are: Leu54, Leu57, Ile61
and Met62 in helix a2; Tyr67, Phe91, and Val93 in b10 sheet; and
His96 and Tyr100 in helix a20. These interactions support the ob-
served changes in the backbone residues known to be in direct
contact with the ligands. Both ligands caused similar changes in
the peptide binding cleft. It was observed that, in our
Mdm2–IMZ simulation, Leu57, Ile61 and Met62 (in helix a2)
showed an inward movement toward the center of the binding
cleft. On the contrary Phe91 showed an outward movement of
about 1.5 Å. The wider difference was found in the case of Phe86,
that showed an inward movement of about 3 Å.
In Mdm2–BDZ simulation Ile61, Met62, Tyr67 and Phe91
showed an inward movement toward the center of the binding
cleft. The larger differences were in His96 and Val93, that showed
an inward movement of about 2 Å. The main conformational
changes were found in linker turn regions or in the b sheets. These
conformational changes seem to be sufﬁcient to accommodate li-
gands that differ in their length: the changes alter the size of the
cleft and indirectly affect the angle of the bottom a helices with re-
spect to the cleft. The analysis of the results obtained by molecular
dynamics of apo system showed a stable and less ﬂexible structure,
with the lid closing the binding cleft of the protein and leading to a
closed conformation of the cleft.
Therefore, as evidenced in this study, upon binding of different
ligands a rearrangement and an outward expansion of the Mdm2
helices, surrounding the binding cleft in bound systems, was ob-
served. Ligand IMZ caused the most prominent changes in the b-
sheets surrounding the binding cleft (b20), whereas BDZ produced
its most signiﬁcant changes in the antiparallel b-sheets, the linker
regions between the b-sheets and the a-helices that form the bot-
tom and side walls of the cleft.
It seems that the Mdm2 domain has an intrinsic ﬂexibility that
enables it to adapt its conformation to ligands. The conformational
changes alter the size of the cleft and were mainly in the linker
regions suggesting that the overall dynamic nature of Mdm2 is
related to dynamic movements in these regions. NMR spectroscopy
studies [25] conﬁrmed the observation that changes in chemical
shift were mainly in the linker regions between the secondary
structure elements and suggests that the overall dynamic natureof Mdm2 is related to dynamic movements in these regions, which
can occur without any loss of the secondary structure scaffold.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bbrc.2012.06.138.
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